TargetPrint^® Provides Quantification of ER, PR and HER2 Status

TargetPrint is a microarray-based gene expression test which offers a quantitative assessment of the patient’s level of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu overexpression within her breast cancer. TargetPrint is offered in conjunction with MammaPrint to provide the physician an even more complete basis for treatment decisions. 

As compared to Immunohistochemistry (IHC), TargetPrint delivers an added benefit to the diagnostic process. IHC provides a semi-quantitative positive or negative result, whereas the gene expression result provided by TargetPrint allows physicians to integrate the absolute level of ER, PR and HER2 gene expression into treatment planning.

ER, PR and HER2 read-outs are determined by measuring the level of gene expression for the three biomarkers. The single read-out is performed on quality-controlled DNA microarrays in Agendia’s state-of-the-art CLIA (Clinical Laboratory Improvement Act) and CAP (College of American Pathologists) registered and compliant genomics laboratories in Irvine, California and Amsterdam, The Netherlands.